InvestorsHub Logo
Followers 6
Posts 1257
Boards Moderated 0
Alias Born 06/14/2009

Re: None

Saturday, 09/12/2020 8:12:07 AM

Saturday, September 12, 2020 8:12:07 AM

Post# of 3683
Friday's news seems great for the CEO

Athersys CEO 'confident' drug will deliver in COVID-19, Spectrum News 1 reports Athersys has focused on creating a stem cell therapy for people suffering from ARDS, the leading cause of death among COVID-19 infection patients, and CEO Gil Van Bokkelen is confident that the company's patented MultiStem therapy will deliver in COVID, Spectrum News 1's Micaela Marshall reports. In May, University Hospitals became the first site for a "MultiStem Administration for COVID-19 Induced Acute Respiratory Distress Syndrome" clinical trial, and Van Bokkelen says "It's been going well. I mean, UH is very active. We got a number of things that are going on that basically give us a lot of hope for this."

Read more at:
https://thefly.com/n.php?id=3159301


Also Behind the scenes the pieces are coming together. Macleod, SIFU, MACOVIA... Posted by u/athersys on Reddit 3 days ago

Athersys files for new Trademark for SIFU
Athersys files for new trademark for SIFU on 9/1:
https://uspto.report/TM/90152411
It also has previously filed for the trademark illustration for SIFU here:
https://uspto.report/TM/88425115

I can see the SIFU development, manufacturing and rollout costs being very high and is another reason Gil is bringing in an EU partner, IMO. This is a type of device technology that can also be licensed out bringing in additional revenue for the company.

SIFU™ trademark registration is intended to cover the categories of medical machines, namely, medical apparatus in the nature of a cryogenic storage and delivery apparatus specially adapted for cryogenic freezing, thawing and dispensing biologic product for medical purposes .. GOOD LUCK LONGS